106308-44-5

106308-44-5 structure

Name: Rufinamide
Chemical Name: Rufinamide
CAS Number: 106308-44-5
Molecular Formula: C₁₀H₈F₂N₄O
Molecular Weight: 238.193
Catalog: Biochemical Inhibitor Transmembrane Transporters Sodium Channel inhibitor
Create Date: 2018-09-18 22:06:43
Modify Date: 2024-01-01 20:15:47
Rufinamide(E 2080; CGP 33101; RUF 331) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).IC50 Value:Target: in vitro:in vivo: Rufinamide and amitriptyline alleviated injury-induced mechanical allodynia for 4 h (maximal effect: 0.10 ± 0.03 g (mean ± SD) to 1.99 ± 0.26 g for rufinamide and 0.25 ± 0.22 g to 1.92 ± 0.85 g for amitriptyline) in mice [1]. Oral rufinamide suppressed pentylenetetrazol-induced seizures in mice (ED(50) 45.8 mg/kg) but not rats, and was active against MES-induced tonic seizures in mice (ED(50) 23.9 mg/kg) and rats (ED(50) 6.1 mg/kg) [2]. Intraperitoneal rufinamide suppressed pentylenetetrazol-, bicuculline-, and picrotoxin-induced clonus in mice (ED(50) 54.0, 50.5, and 76.3 mg/kg, respectively).Clinical trial: Exploratory Study to Evaluate the Effect of SYN-111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD). Phase 2

Name	Rufinamide
Synonyms	1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide Rufinamide 1H-1,2,3-Triazole-4-carboxamide, 1-[(2,6-difluorophenyl)methyl]- 1-((2,6-Difluorophenyl)methyl)-1H-1,2,3-triazole-4-carboxamide Banzel Inovelon

Description	Rufinamide(E 2080; CGP 33101; RUF 331) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).IC50 Value:Target: in vitro:in vivo: Rufinamide and amitriptyline alleviated injury-induced mechanical allodynia for 4 h (maximal effect: 0.10 ± 0.03 g (mean ± SD) to 1.99 ± 0.26 g for rufinamide and 0.25 ± 0.22 g to 1.92 ± 0.85 g for amitriptyline) in mice [1]. Oral rufinamide suppressed pentylenetetrazol-induced seizures in mice (ED(50) 45.8 mg/kg) but not rats, and was active against MES-induced tonic seizures in mice (ED(50) 23.9 mg/kg) and rats (ED(50) 6.1 mg/kg) [2]. Intraperitoneal rufinamide suppressed pentylenetetrazol-, bicuculline-, and picrotoxin-induced clonus in mice (ED(50) 54.0, 50.5, and 76.3 mg/kg, respectively).Clinical trial: Exploratory Study to Evaluate the Effect of SYN-111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD). Phase 2
Related Catalog	Signaling Pathways >> Others >> Others Natural Products >> Alkaloid Research Areas >> Neurological Disease
References	[1]. Suter MR, Kirschmann G, Laedermann CJ, Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology. 2013 Jan;118(1):160-72. [2]. White HS, Franklin MR, Kupferberg HJ, The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008 Jul;49(7):1213-20.

Density	1.5±0.1 g/cm3
Boiling Point	473.8±55.0 °C at 760 mmHg
Melting Point	232-234?C
Molecular Formula	C₁₀H₈F₂N₄O
Molecular Weight	238.193
Flash Point	240.4±31.5 °C
Exact Mass	238.066620
PSA	73.80000
LogP	0.05
Vapour Pressure	0.0±1.2 mmHg at 25°C
Index of Refraction	1.635
Storage condition	−20°C
Water Solubility	DMSO: soluble9mg/mL

Hazard Codes	F,T
Risk Phrases	11-23/24/25-39/23/24/25-48-41-38-28
Safety Phrases	7-16-36/37-45-36/37/39-28-26-24/25
RIDADR	UN 1648 3 / PGII

1795037-48-7	106308-44-5
106308-41-2	217448-86-7